Stockscreener 앱 받기
0.8266
6.14%
-0.0541
시간 외 거래:
.83
0.0034
+0.41%
전일 마감가:
$0.8807
열려 있는:
$0.84
하루 거래량:
2.67M
Relative Volume:
0.25
시가총액:
$81.00M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-13.90%
1개월 성능:
+6.63%
6개월 성능:
-77.04%
1년 성능:
-73.16%
1일 변동 폭
$0.8175
$0.8696
1주일 범위
$0.8175
$0.9995
52주 변동 폭
$0.6816
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.8266 | 86.30M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | 개시 | Leerink Partners | Outperform |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 개시 | Wells Fargo | Overweight |
| 2024-09-05 | 개시 | Jefferies | Buy |
| 2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-10 | 개시 | Laidlaw | Buy |
| 2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 개시 | ROTH Capital | Buy |
| 2020-03-02 | 개시 | Oppenheimer | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 개시 | Piper Jaffray | Overweight |
| 2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 개시 | Citigroup | Neutral |
| 2015-06-01 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, - GlobeNewswire
Deadline Alert: aTyr Pharma Inc. (ATYR) Shareholders Who - GlobeNewswire
ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ATyr Pharma - FinancialContent
Atyr Pharma Inc (ATYR) can make a big difference with a little luck - setenews.com
Using portfolio simulators with aTyr Pharma Inc. included2025 Major Catalysts & Reliable Entry Point Trade Alerts - newser.com
Will aTyr Pharma Inc. bounce back from current support2025 AllTime Highs & Safe Capital Growth Tips - newser.com
Levi & Korsinsky Urges aTyr Pharma, Inc. (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - Stockhouse
aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Investor Alert: Deadline Approaching to Join aTyr Pharma, Inc. (ATYR) Class ActionContact Levi & Korsinsky - The Globe and Mail
ATYR Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ATYR To Contact Him Directly To Discuss Their Options - MarketScreener
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineATYR - MarketScreener
Does aTyr Pharma Inc. fit your quant trading modelJuly 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Ranking aTyr Pharma Inc. among high performing stocks via tools2025 Trading Recap & Low Risk High Win Rate Picks - newser.com
Will aTyr Pharma Inc. (471A) stock maintain strong growthWeekly Trend Report & Technical Entry and Exit Tips - newser.com
How aTyr Pharma Inc. (471A) stock reacts to stronger dollarMarket Risk Report & Reliable Price Breakout Signals - newser.com
What earnings revisions data tells us about aTyr Pharma Inc.July 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
aTyr Pharma, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsATYR - Lelezard
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR)Join by December 8, 2025Contact Levi & Korsinsky - Stockhouse
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Relative strength of aTyr Pharma Inc. in sector analysisEarnings Risk Report & Stepwise Trade Execution Plans - newser.com
Is aTyr Pharma Inc. stock a defensive play in 2025Weekly Profit Analysis & Weekly High Return Forecasts - newser.com
ATYR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that aTyr Pharma, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages aTyr Pharma, - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile
Is aTyr Pharma Inc. stock cheap at current valuation2025 Winners & Losers & Precise Trade Entry Recommendations - newser.com
What catalysts could drive aTyr Pharma Inc. stock higherMarket Sentiment Summary & Reliable Entry Point Alerts - newser.com
Real time breakdown of aTyr Pharma Inc. stock performance2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com
Is aTyr Pharma Inc. stock poised for growthGDP Growth & Weekly Market Pulse Alerts - newser.com
aTyr Pharma Inc. stock prediction for this weekGDP Growth & Verified High Yield Trade Plans - newser.com
Lost Money on aTyr Pharma, Inc. (ATYR)? Contact Levi & Korsinsky to Join Class Action Before December 8, 2025 - ACCESS Newswire
December 8, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ATYR - Bluefield Daily Telegraph
Levi & Korsinsky Notifies aTyr Pharma, Inc. (ATYR) InvestorsLead Plaintiff Deadline on December 8, 2025 - Stockhouse
ATYR Shareholder Alert: New aTyr Pharma, Inc. (ATYR) - GlobeNewswire
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile
aTyr Pharma (ATYR) to Release Earnings on Thursday - MarketBeat
Will aTyr Pharma Inc. stock go up soon2025 Price Action Summary & Low Risk Entry Point Tips - newser.com
Will aTyr Pharma Inc. (471A) stock outperform benchmarksInsider Selling & Weekly Chart Analysis and Guides - newser.com
ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages aTyr Pharma, - GlobeNewswire
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming ... - Caledonian Record
The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ATYR - GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming DeadlinesATYR - FinancialContent
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors - GlobeNewswire
ATYR Shareholder Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged — Hagens Berman - Morningstar
Why aTyr Pharma Inc. stock could see breakout soonWeekly Investment Report & Entry Point Confirmation Signals - newser.com
ATYR Shareholder Alert: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman - Sahm
Atyr Pharma Inc (ATYR) 재무 분석
Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):